Surrozen, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $321.9M
- Price
- $27.39
- % Change (Daily % change from the live per-ticker quote feed.)
- -5.99%
- Volume
- 14.7K
About
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs’ endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Quick stats
Shares outstanding11.8M
Computed float2.8M
Float / shares23.4%
Cash runway (months)32.5
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001824893
Websitehttps://www.surrozen.com
AI Summary
AI-generated1/11
majorbullishclinical trial
Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema
Surrozen's IND application for SZN-8141, a bifunctional Wnt agonist/VEGF antagonist for diabetic macular edema, has been cleared by the FDA, with first patient dosing in the Phase 1b/2a DUET study expected in Q4 2026.
The clearance also satisfies the milestone triggering the second closing of the March 2025 private placement, expected to provide approximately $95.1 million in gross proceeds on or about October 20, 2026.
Proceeds will fund SZN-8141 and SZN-8143 development; the company will file a resale registration statement within 30 days of closing, creating potential share overhang. Initial DUET data is expected in the second half of 2027.
Red flags
- resale registration statement following second closing creates potential share overhang/dilution
- early-stage asset with initial clinical data not expected until H2 2027